Innoviva to Attend Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA), a diversified holding company, has announced that its Chief Executive Officer, Pavel Raifeld, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event will be held in Miami, FL, on Monday, June 10, 2024, at 1:20 p.m. Eastern Time. Interested parties can access a live webcast of the chat under the "Events & Presentations" section in the Investor Relations area of the company's website. The webcast will remain available for replay for 90 days after the event.

Innoviva operates as a diversified holding company primarily focused on a robust royalties portfolio and a specialized platform in critical care and infectious diseases known as Innoviva Specialty Therapeutics (IST). Additionally, the company maintains a strategic portfolio of healthcare investments.

A significant part of Innoviva’s royalty portfolio involves respiratory assets in collaboration with Glaxo Group Limited (GSK). From this partnership, Innoviva receives royalties from GSK on the sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. 

In addition to its royalty interests, Innoviva has expanded its portfolio to include critical care and infectious disease assets. These assets are primarily derived from its acquisition of Entasis Therapeutics and La Jolla Pharmaceutical Company. From Entasis Therapeutics, Innoviva now markets XACDURO® (sulbactam for injection; durlobactam for injection), which is approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex. Additionally, Innoviva is developing zoliflodacin, an investigational drug for treating uncomplicated gonorrhea.

From La Jolla Pharmaceutical Company, Innoviva has incorporated GIAPREZA® (angiotensin II), approved to increase blood pressure in adults suffering from septic shock or other forms of distributive shock. Another notable asset from La Jolla is XERAVA® (eravacycline), designated for the treatment of complicated intra-abdominal infections in adults.

The trademarks ANORO®, RELVAR®, and BREO® are owned by the GSK group of companies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!